What are the recommended HCC surveillance guidelines for patients with treated hepatitis C virus infection who have achieved sustained virologic response and do not have cirrhosis?

HCC Surveillance for Non-Cirrhotic HCV Patients with SVR

HCC surveillance is currently NOT recommended for non-cirrhotic HCV patients who achieve sustained virologic response (SVR), as their annual HCC incidence falls below the cost-effectiveness threshold of 0.7-1.5% per year. 1

Evidence-Based Rationale

The most recent 2025 EASL guidelines explicitly state that patients with chronic liver disease and advanced fibrosis without cirrhosis cannot currently be recommended for HCC surveillance owing to insufficient evidence 1. This represents the highest quality guideline evidence available.

Key Supporting Data

HCC Incidence in Non-Cirrhotic SVR Patients:

• Patients with F3 fibrosis post-SVR have an HCC incidence of 0.5 per 100 person-years (0.5% annually) 1
• This rate is similar whether SVR was achieved with interferon-based therapy (0.4%) or DAA therapy (0.5%) 1
• This falls below the 0.7-1.5% annual threshold required for cost-effective surveillance 2, 3

Prospective surveillance studies of F3 patients post-SVR showed:

• Spanish study: 0.47 per 100 person-years among 506 F3 patients 1
• French study: 0.52 per 100 person-years among 1,086 F3 patients 1
• Another Spanish study: zero HCC cases in 63 F3 patients during follow-up 1

Important Clinical Caveats

When to Consider Surveillance Despite Non-Cirrhotic Status

While routine surveillance is not recommended, certain high-risk subgroups may warrant individualized consideration:

Age-Based Risk Stratification:

• Men ≥60 years with F3 fibrosis have HCC incidence rates of 1.3-2.9 per 100 person-years, exceeding surveillance thresholds 4
• Women show lower rates (0.32-0.58 per 100 person-years) even at advanced ages 4

Risk-Enhancing Factors:

• Diabetes mellitus 5, 3
• Hepatic steatosis 3
• Alcohol use 3
• Elevated AFP ≥6 ng/mL 2
• FIB-4 ≥2.5 2

For patients <65 years: The SFA score (male sex: 1 point; AFP ≥6: 1 point; FIB-4 ≥2.5: 2 points) identifies high-risk patients. SFA score ≥3 indicates 2.9% annual HCC incidence, justifying surveillance 2

For patients ≥65 years: AFP ≥6 ng/mL alone predicts high risk with 3.5% annual incidence 2

Critical Distinction: Fibrosis Assessment Timing

The fibrosis stage BEFORE antiviral treatment—not after SVR—determines surveillance recommendations 1. This is crucial because:

• Fibrosis can regress after SVR, potentially leading to underestimation of HCC risk
• Some patients develop HCC despite fibrosis regression 6
• Pre-treatment cirrhosis mandates lifelong surveillance regardless of post-SVR fibrosis improvement

Contrast with Cirrhotic Patients

For comparison, patients with pre-treatment cirrhosis who achieve SVR absolutely require continued HCC surveillance 7, 8:

• Annual HCC incidence: 1.39% in cirrhotic SVR patients 8
• Surveillance with ultrasound every 6 months is mandatory 7, 1
• Risk persists for at least 15 years post-SVR 8

Practical Recommendation

For the standard non-cirrhotic HCV patient with SVR:

• No routine HCC surveillance required
• Annual clinical follow-up to monitor for development of other liver disease risk factors
• Reassess fibrosis status if new risk factors emerge (alcohol use, weight gain, diabetes)

Exception—Consider surveillance if:

• Male ≥60 years old
• AFP ≥6 ng/mL AND FIB-4 ≥2.5 (especially if age <65)
• Multiple metabolic risk factors (diabetes, obesity, ongoing alcohol use)
• In these cases: ultrasound every 6 months ± AFP 1

This approach balances the low baseline HCC risk in non-cirrhotic SVR patients against the need to identify the small subset with sufficiently elevated risk to justify surveillance costs and potential harms from false-positive results.